Tunneled central venous catheters with ports are increasingly used for therapeutic apheresis procedures. Vortex ports have been used as access for therapeutic apheresis procedures, but are not ideal for therapeutic plasma exchange (TPE) procedures due to lower flow rates. We performed an in vitro experiment to compare flow characteristics of the single-lumen Vortex port (AngioDynamics) with the single-lumen TidalPort (Norfolk Medical). We used expired red blood cell units and adjusted the hematocrit to 40% with normal saline in a 2-L bag. We programmed the Spectra Optia (Terumo BCT) to run a 1.0-volume TPE with 5% albumin as replacement fluid. The TidalPort achieved flow rates of up to 110 mL/min without triggering alarms. Due to crucial alarms, the Vortex Port was not able to run at a flow rate higher than 90 mL/min, and multiple caution alarms were triggered at flow rates of 80 to 90 mL/min. These findings suggest that the TidalPort may be a suitable access option that provides flow rates similar to peripheral or central venous catheters for TPE procedures.
T unneled central venous catheters with ports (port-CVCs), commonly referred to as "ports," are often used in patients who need long-term access for therapeutic apheresis procedures because they do not have adequate venous access. PortCVCs were initially used to deliver parenteral nutrition and chemotherapy. 1, 2 Their use has rapidly grown, with more than 200,000 ports being placed annually. 3 PortCVCs offer distinct advantages for patients requiring longterm, intermittent venous access. Since there are no external components, port-CVCs can "normalize" patients' activities, allowing for bathing and swimming, and improve body image. The Centers for Disease Control and Prevention guidelines also recommend use of port-CVCs since they have the lowest risk for catheter-related bloodstream infection. 4 Their use crossed over into the therapeutic apheresis arena initially as access for red blood cell (RBC) exchanges. Vortex ports (AngioDynamics, Latham, NY) are available as single or dual lumens and are made of either titanium or plastic. Vortex ports have a rounded chamber designed to eliminate dead space and resist sludge buildup. The outlet is set tangentially, rather than perpendicularly, to create swirling flow within the chamber, which prevents sludge buildup and reduces rate of occlusion. 5 Vortex ports have better flow characteristics than conventional cylindrical chamber ports of similar size. 3 At our institution, we use dual-lumen Vortex ports (AngioDynamics, Latham, NY) for RBC exchange (RBCx) and extracorporeal photopheresis (ECP) that require flow rates of less than 60 mL/min. We have occasionally used singlelumen ports connected to a 9.6F silicone catheter for therapeutic plasma exchange (TPE) procedures and typically achieved inlet flow rates of approximately 60 mL/min. Typically, TPE is run at higher flow rates (>80 mL/min).
The TidalPort (Norfolk Medical, Skokie, IL), originally known as the SportPort, was first introduced in 2013. The TidalPort is made of titanium and has a spherical internal chamber with no corners and an outlet at the chamber floor (Fig. 1) . A TidalPort connected to a 9F catheter is expected to provide flow rates of up to 100 mL/min, which are desirable for TPE. Based on the design, potential advantages include improved flow characteristics, decreased sludge/clot formation, and hence, decreased need for tissue plasminogen activator (tPA). Due to these potential advantages and our experience of requiring tPA for Vortex ports in patients undergoing RBCx and ECP, we performed an in vitro comparison between the Vortex LP port and the TidalPort to determine if some of these advantages could be confirmed before incorporation of the TidalPort into clinical use at our institution.
STUDY DESIGN
We performed an in vitro comparison between two singlelumen TidalPorts and two single-lumen Vortex LP titanium ports connected to a 9F polyurethane catheter. Simulation of patient blood volume was created using three units of expired RBCs reconstituted to a hematocrit (Hct) of 40% using normal saline in a 2-L bag (transfer pack). Inlet and return lines of a Spectra Optia (Terumo BCT, Lakewood, CO) TPE disposable kit were connected to the test ports via 16-gauge noncoring needles. Catheters were inserted into the 2-L bag of reconstituted blood, and the blood bag was continuously manually mixed to ensure a homogenous solution (Fig. 2) . The Spectra Optia was programmed for 1.0-volume TPE with 5% albumin as a replacement fluid. The Spectra Optia pressure limits were maintained at manufacturer's defaults: inlet of -250 mm Hg and return of 400 mm Hg. Five separate experimental 1.0-volume TPE runs were performed with flow rates raised in increments of 10 mL/min from 70 to 110 mL/ min (Table 1) . Inlet and return pressures and any alarms were recorded. Visual inspection for leaks, damage, or occlusions was also performed at each flow rate interval.
RESULTS
Inlet and return pressures at the various flow rates for the different ports are given in Table 1 and inlet pressures compared in Fig. 3 . All five runs were completed successfully with TidalPort, whereas only three runs were completed with Vortex. The runs with 100 and 110 mL/min were not successful with Vortex due to crucial pressure alarms. In addition, multiple warning alarms fired at flow rates of 80 to 90 mL/min with Vortex. There were no alarms during the runs with the TidalPort, and flow rates of 110 mL/min were achieved. At the completion of runs, no leaks, damages, or occlusions within either port were noted; however, hemolysis variables were not examined due to the reconstituted nature of the blood.
DISCUSSION
This study is the first in vitro comparison between the Vortex LP titanium port and the TidalPort. Our findings demonstrated higher flow characteristics for the TidalPort, with lower inlet pressures and faster flow rates. This could translate clinically to shortened procedure run times. This study was not designed to assess sludge buildup and tPA requirement: in vivo studies will be required to examine how the differences in design translate into performance of the port. In vivo comparisons may be confounded by individual patient characteristics, such as blood viscosity, that may affect in vivo flow characteristics and development of sludge or thrombosis. A limitation of our study is that whole blood, with plasma and platelets, was not used. This could translate to an inability to achieve the faster inlet flow rates in vivo.
There is a paucity of literature on in vitro or clinical experience with port-CVCs for therapeutic apheresis procedures. A comparison of dual-lumen Vortex LP titanium ports (AngioDynamics) with temporary central venous catheters and peripheral catheters for RBCx showed similar end-hematocrits and hemoglobin S results, but procedures performed with dual-lumen Vortex LP titanium ports had lower inlet speeds, longer mean duration, increased rates of alarms, and need for tPA. 6 In addition, seven of these ports were removed: six due to infection and one due to malfunction. In another study, the Vortex TR, with a 9.6F silicone catheter (AngioDynamics), was used in four patients to perform 37 ECP procedures. Twenty-six procedures experienced pressure alarms and other technical problems, leading to discontinuation of 13 procedures before photoactivation of the buffy coat. The fourth patient completed more procedures successfully, likely due to the growing experience and incorporation of flushing the port before use. 7 Two studies evaluated the CathLink 20 (Bard Peripheral Vascular, Tempe, AZ) in TPE; however, it is no longer manufactured. 8, 9 In April 2017, it was replaced by the FDA-approved PowerFlow implantable apheresis IV port (Bard Peripheral Vascular, Tempe, AZ). The PowerFlow is marketed as a high-flow, power-injectable port specifically defined for therapeutic apheresis. The body consists of a titanium funnel encased by silicone attached to a 9.6F ChronoFlex catheter, which is made of polyurethane and has a 2.0-mm inner diameter. The funnel shape assists in guiding IV catheter access, and a needle stop prevents needles from piercing the valve. Per the manufacturer, flow rates of up to 150 mL/min can be achieved and accessed 1,000 times. 10 This port was not available at the time of our study. Based on manufacturer information, both the TidalPort and the PowerFlow ports can achieve flow rates of more than 100 mL/min. Our study confirmed TidalPort can achieve this; however, in vitro assessment may overestimate achievable flow rates in clinical practice due to influence of other variables, such as positioning of the port, fibrin sheath formation, or sludging that may build up over time. Since this was a small in vitro pilot study, additional clinical studies are needed to confirm our findings and to evaluate the flow characteristics of the newly available PowerFlow port.
Our apheresis center performs approximately 3,200 therapeutic procedures every year, including TPE, RBCx, and ECP. We reserve use of port-CVCs in patients who need long-term access and who do not have adequate peripheral veins. Our practice of choosing port-CVCs involves determining the number of lumens needed and the type of procedure to be performed. Most of our RBCx patients do not have any suitable peripheral access; therefore, the dual lumens offered by the Vortex port are used to provide both inlet and return access. Currently, we do not have any preference for either Vortex or TidalPort for ECP. We generally do not use Vortex ports for TPE due to flow rate restrictions (up to 60 mL/min). Due to our in vitro observations of higher flow rates and less alarms with TidalPorts, we have been using TidalPorts for TPE procedures; however, there are insufficient data at this stage for sharing. In addition, we are currently evaluating the PowerFlow port for TPE procedures.
In conclusion, this in vitro pilot study has demonstrated higher in vitro flow characteristics of the TidalPort compared with the Vortex port. Clinical studies are now needed to demonstrate reproducibility of these findings in vivo and to assess the rate of sludge and occlusion formation necessitating tPA use.
